Thoratec Expecting Near-Term Completion Of Expanded LVAD Indication Trial
This article was originally published in The Gray Sheet
Executive Summary
Thoratec anticipates completing enrollment for its HeartMate VE left ventricular assist device (LVAD) clinical trial by the end of July, citing the fact that one of the study's predefined endpoints, 92 patient deaths, has almost been reached.
You may also be interested in...
Thoratec REMATCH Preliminary Data Pumps Up Stock 43% In June
Encouraging preliminary data from Thoratec's REMATCH trial for treatment of congestive heart failure with the HeartMate VE left ventricular assist system (LVAS) helped the firm's stock beat ahead 42.7% in June. The issue closed at $15.55 for the month, up $4.65.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.